VEGFA and nonpapillary renal cell carcinoma: Moreover, the development of therapies targeted against the tyrosine kinase activity of vascular endothelial growth factor (VEGF) and novel immune checkpoint inhibitors significantly increased the overall survival of patients with metastatic ccRCC.